EMPOUIK

Welcome to the Brand page for “EMPOUIK”, which is offered here for The mark consists of the word empouik in stylized font with a fanciful design comprising part of the letter u.;pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; pharmaceutical preparations for human use, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; pharmaceutical preparations for human use that modulate the immune system; pharmaceutical and biological preparations for human use for immunotherapy, t cell therapy; pharmaceutical preparations for human use, stem cells for medical or clinical use; pharmaceutical preparations for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders;color is not claimed as a feature of the mark.;.

Its status is currently believed to be active. Its class is unavailable. “EMPOUIK” is believed to be currently owned by “BRISTOL-MYERS SQUIBB COMPANY”.